1Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol, 1997,80(9A): 111-6i.
2Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide - dependment vasodilatation by HMG - COA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 2000, 20:61 -9.
3Vasa M, Fichtlscherer S, Aicher A, et al. Increase in ciculating endothelialprogenitor cells by statin therapy in patients with stable coronary artery disease. Circulation, 2001, 103: 2885-90.
4Suwaidi JA, Hamasaki S, Higano ST, et al. Long- term follow up of patiems with mild coronary artery disease and endothelial dysfunction. Circulation, 2000, 101:948-54.
5Liuzzo G. Alherosclerosis:an inflammatory disease. Rays, 2001,26:221-30.
6Wassmann S, Nickenig G. Improvement of endothelial function by HMG- COA reductase inhibitors. Drug News Perspect,2002, 15:85 - 92.
7Strandberg TE,Vanhanen H, Tikkanen M J. Effect of statins on C - reactive prmein in patients with coronary heart disease.l.ancet,1999,353:118-9.
8de Maat MP, Kluft C.Determinents of C - reactive protein concentration in blood. Ital Heart J, 2001,2: 189-95.
2[2]Dupuis J,Tardif JC,Cernack P,et al.cholesterol redaction rapidly improves endothelial function after acute coronary syndromes:the RECIFE trial[J].Circulation,1999,99:3227-3333.
3[3]Flaker GC,Wamica JW,Sacks FM,et al.For the cholesterol and Recueht Event(CARE)investigators.Pravastain prevents clinical events in revascularized patients with average cholesterol concentrations[J].J Am Coil Cardiol,1999,34:106-112.
